TAKEDA PHARMACEUTI SPON ADR EA REPR 0.5 ORD (TKPYY)

21.20
OTC Markets
Prev Close 21.02
Day Low/High 20.92 / 21.20
52 Wk Low/High 20.32 / 26.52
Exchange OTC Markets
Shares Outstanding 1580.69B
Market Cap 33.22B
Div & Yield N.A. (N.A)

Latest News

Takeda Licenses Global Rights To Theravance Biopharma's TD-8954, A Novel 5-HT4 Agonist And Motility Agent For Gastrointestinal Motility Disorders

Takeda Licenses Global Rights To Theravance Biopharma's TD-8954, A Novel 5-HT4 Agonist And Motility Agent For Gastrointestinal Motility Disorders

Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area

Takeda To Present New Data At The American Diabetes Association's 76th Scientific Sessions

Takeda To Present New Data At The American Diabetes Association's 76th Scientific Sessions

Eight abstract presentations include new analyses from the EXAMINE trial and real-world databases

Roivant Sciences And Takeda Launch Myovant Sciences To Develop Innovative Therapeutics For Women's Health And Prostate Cancer

Roivant Sciences And Takeda Launch Myovant Sciences To Develop Innovative Therapeutics For Women's Health And Prostate Cancer

- Myovant to conduct global phase 3 programs of relugolix, a potential best-in-class GnRH antagonist for the treatment of uterine fibroids, endometriosis and prostate cancer

Stocks Inch Higher as Yellen Hints at Summer Rate Hike

Stocks Inch Higher as Yellen Hints at Summer Rate Hike

Stocks inch higher by mid-afternoon Friday as Federal Reserve Chair Janet Yellen suggest the central bank could implement another rate hike this summer.

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.

Takeda Pharmaceuticals U.S.A., Inc. Announces Plans To Transform Business, Enhancing Value For Patients

Takeda Pharmaceuticals U.S.A., Inc. Announces Plans To Transform Business, Enhancing Value For Patients

Moves to Strengthen Portfolio Focus, Transfer Rights for CONTRAVE® and Invest in Recent Launches in United States

Orexigen And Takeda Jointly Announce Orexigen's Acquisition Of All Rights To CONTRAVE® In The United States

Orexigen And Takeda Jointly Announce Orexigen's Acquisition Of All Rights To CONTRAVE® In The United States

Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets

FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)

FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)

New melt in your mouth tablet for appropriate adult patients with heartburn associated with Gastroesophageal Reflux Disease (GERD)

Tourmaline Fact Sheet

Tourmaline Fact Sheet

Takeda Pharmaceutical Company Limited ( TSE: 4502) today announced that the U.

Actress Sara Rue Urges Women To Resolve Now Rather Than Wait Until The New Year To Start A Weight Loss Program

Actress Sara Rue Urges Women To Resolve Now Rather Than Wait Until The New Year To Start A Weight Loss Program

New Campaign Developed to Inspire Obese and Overweight Women to Take Action and Talk with Their Doctor

Takeda Celebrates Fifth Annual Takeda Cares Day By Expanding Nationwide And Raising More Than $250,000 For Chicagoland Nonprofits

Takeda Celebrates Fifth Annual Takeda Cares Day By Expanding Nationwide And Raising More Than $250,000 For Chicagoland Nonprofits

Company Has Donated More Than $500,000 to Local Charities Since Program Began

Orexigen And Takeda Announce An Amended And Restated Collaboration Agreement

Orexigen And Takeda Announce An Amended And Restated Collaboration Agreement

Partnership Reaffirms Commitment to the Success of CONTRAVE® (naltrexone HCl / bupropion HCl extended-release tablets)

Takeda Announces Completion Of The Pioglitazone Post-Marketing Commitment And Submission Of Results To The EMA, The FDA And The PMDA

Takeda Announces Completion Of The Pioglitazone Post-Marketing Commitment And Submission Of Results To The EMA, The FDA And The PMDA

Second Study Indicates No Increased Risk of Bladder Cancer in Patients Treated With Pioglitazone, Further Reinforcing the Positive Benefit/Risk Profile

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off

Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.

Takeda Pharmaceutical (TKPYY) Stock Down After U.S. Federal Jury Imposes $6 Billion In Damages

Takeda Pharmaceutical (TKPYY) Stock Down After U.S. Federal Jury Imposes $6 Billion In Damages

Shares of Takeda Pharmaceutical (TKPYY) are down as the company said it would fight $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging the drugmaker concealed cancer risks associated with its Actos diabetes drug,

Why Eli Lilly (LLY) Stock May Be Lower Today

Why Eli Lilly (LLY) Stock May Be Lower Today

Shares of Eli Lilly (LLY) may fall today after a jury ordered the company to pay $3 billion and Takeda (TKPYY) to pay $6 billion in punitive damages over allegations that they hid the cancer risks associated with the diabetes therapy Actos.

Affymax, Takeda Recall Anemia Drug

Affymax, Takeda Recall Anemia Drug

Drug companies Affymax and Takeda issue a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients.